JAK1 and ulcerative colitis: Upadacitinib is an oral, second-generation JAK1 inhibitor currently approved by the FDA and EMA for the treatment of rheumatoid arthritis, axial spondylarthritis, Crohn’s disease (CD), ulcerative colitis, and atopic dermatitis in adult patients.